IMUX
IMMUNIC, INC.
Overview
IMMUNIC, INC is a Healthcare company operating in Biotechnology with a $200.9M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
12 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q3 FY2024Earnings2024-11-0912 Q&A exchanges
- Q1 FY2024Earnings2024-05-088 Q&A exchanges
- Q4 FY2023Earnings2024-02-2219 Q&A exchanges
- Q3 FY2023Earnings2023-11-1412 Q&A exchanges
- Q2 FY2023Earnings2023-08-067 Q&A exchanges
- Q1 FY2023Earnings2023-05-1413 Q&A exchanges
- Q4 FY2022Earnings2023-02-2313 Q&A exchanges
- Q3 FY2022Earnings2022-11-069 Q&A exchanges
- Q2 FY2022Earnings2022-08-0614 Q&A exchanges
- Q1 FY2022Earnings2022-05-1021 Q&A exchanges
- Q4 FY2021Earnings2022-02-2430 Q&A exchanges
- Q3 FY2021Earnings2021-11-0619 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-1.24—Rev— vs ——EODHD
- Q1 FY20262026-05-06EPS$-1.08 vs $-0.10-100.0%Rev$0 vs ——EODHD
- Q4 FY20252026-02-18EPS$-0.07 vs $-0.09+25.9%Rev$0 vs ——EODHD
- Q3 FY20252025-11-12EPS$-0.13 vs $-0.15+13.3%Rev$0 vs ——EODHD
- Q2 FY20252025-08-06EPS$-0.20 vs $-0.17-17.6%Rev$0 vs ——EODHD
- Q1 FY20252025-06-10EPS$-0.25 vs $-0.24-4.2%Rev$0 vs ——EODHD
- Q4 FY20242025-03-19EPS$-0.25 vs $-0.24-6.1%Rev$114.0K vs ——EODHD
- Q3 FY20242024-11-06EPS$-0.24 vs $-0.22-9.1%Rev$0 vs ——EODHD
- Q2 FY20242024-08-07EPS$-0.21 vs $-0.23+8.7%Rev$0 vs ——EODHD
- Q1 FY20242024-05-07EPS$-0.30 vs $-0.26-15.4%Rev$0 vs ——EODHD
- Q4 FY20232024-02-21EPS$-0.48 vs $-0.51+5.9%Rev$0 vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.51 vs $-0.55+7.3%Rev$0 vs ——EODHD
- Q2 FY20232023-08-02EPS$-0.54 vs $-0.52-3.9%Rev$0 vs ——EODHD
- Q1 FY20232023-05-10EPS$-0.58 vs $-0.52-11.5%Rev$0 vs ——EODHD
- Q4 FY20222023-02-22EPS$-1.62 vs $-0.73-100.0%Rev$0 vs ——EODHD
- Q3 FY20222022-11-02EPS$-0.69 vs $-0.66-4.5%Rev$0 vs ——EODHD
- Q2 FY20222022-08-03EPS$-0.72 vs $-0.720.0%Rev$0 vs ——EODHD
- Q1 FY20222022-05-09EPS$-0.74 vs $-0.80+7.5%Rev$0 vs ——EODHD
- Q4 FY20212022-02-23EPS$-0.72 vs $-0.76+5.3%Rev$0 vs ——EODHD
- Q3 FY20212021-11-03EPS$-0.76 vs $-0.78+2.6%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-1.24 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-1.08 | $-0.10 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-02-18 | $-0.07 | $-0.09 | +25.9% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.13 | $-0.15 | +13.3% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.20 | $-0.17 | -17.6% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-06-10 | $-0.25 | $-0.24 | -4.2% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-19 | $-0.25 | $-0.24 | -6.1% | $114.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.24 | $-0.22 | -9.1% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.21 | $-0.23 | +8.7% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.30 | $-0.26 | -15.4% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $-0.48 | $-0.51 | +5.9% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.51 | $-0.55 | +7.3% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.54 | $-0.52 | -3.9% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.58 | $-0.52 | -11.5% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $-1.62 | $-0.73 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.69 | $-0.66 | -4.5% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.72 | $-0.72 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.74 | $-0.80 | +7.5% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $-0.72 | $-0.76 | +5.3% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-0.76 | $-0.78 | +2.6% | $0 | — | — | EODHD |
Source: EODHD. IMUX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks IMUX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2024 | $4.05 | $3.24 | +25.0% | -3.6% | -1.0% |
| Q4 FY2024 | $4.63 | $3.44 | +34.7% | +2.0% | +4.6% |
| Q3 FY2024 | $4.35 | $3.41 | +27.6% | -4.4% | -3.3% |
| Q2 FY2024 | $4.31 | $3.35 | +28.8% | -2.0% | -3.5% |
| Q1 FY2023 | $4.40 | $3.47 | +26.9% | +3.9% | +2.1% |
| Q4 FY2023 | $4.54 | $3.37 | +34.8% | +1.6% | +3.0% |
| Q3 FY2023 | $4.24 | $3.38 | +25.4% | -4.4% | -6.5% |
| Q2 FY2023 | $4.45 | $3.56 | +24.9% | -4.5% | -1.7% |
| Q1 FY2022 | $4.39 | $3.54 | +23.9% | +3.3% | +3.3% |
| Q4 FY2022 | $4.82 | $3.58 | +34.7% | +2.3% | +2.3% |
Guidance change history
Sample- Q1 FY2024Raised2024-04-15
- Q4 FY2024Raised2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Raised2024-07-15
- Q1 FY2023Raised2023-04-15
- Q4 FY2023Raised2023-13-15
- Q3 FY2023Raised2023-10-15
- Q2 FY2023Raised2023-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Daniel VittCEO1 yr 6 mo11 callsCurrentSample
CEO since 2024 • 2/2 beats (100%) • last guidance cut Q1 FY2024
- Glenn WhaleyCFO1 yr 6 mo12 callsCurrentSample
CFO since 2024 • 1/2 beats (50%) • last guidance cut Q1 FY2024
- Jason TardioCOO1 yr 11 mo1 callCurrentSample
COO since 2024 • 1/2 beats (50%) • last call held guidance Q3 FY2024
- Michael A PanzaraChief Medical Officer2 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance cut Q2 FY2024
- Andreas MuehlerChief Medical Officer1 yr 6 mo3 callsCurrentSample
OTHER_C_SUITE since 2024 • 1/2 beats (50%) • last call held guidance Q3 FY2024
- Duane NashExecutive Chairman1 yr 6 mono recorded callsCurrentSample
OTHER since 2024 • 1/2 beats (50%) • last guidance cut Q2 FY2024
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IMUX.
$ curl https://api.spokenalpha.com/v1/companies/IMUXFAQ
Frequently asked about IMUX
Where can I find IMMUNIC, INC.'s (IMUX) earnings call transcripts?
Spoken Alpha indexes IMUX's earnings call transcripts at https://spokenalpha.com/companies/IMUX. Each call links to attributed speakers and parsed analyst Q&A. IMMUNIC, INC.'s own investor relations page is at https://ir.imux.com/.
When was IMMUNIC, INC.'s most recent earnings call?
IMMUNIC, INC. (IMUX) held its most recent earnings call on 2024-11-09, covering fiscal Q3 2024.
What sector is IMUX in?
IMMUNIC, INC. (IMUX) operates in the Healthcare sector (Biotechnology industry).